JP MORGAN/CALL/BECTON DICKINSON AND CO./320/0.1/17.01.25 Share Price

Warrant

DE000JL7YWB2

Real-time Bid/Ask 02:00:31 21/05/2024 pm IST
0.17 EUR / 0.67 EUR +133.33% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./320/0.1/17.01.25
1 month-25.00%
3 months-68.97%
Date Price Change
21/24/21 0.18 0.00%
20/24/20 0.18 +5.88%
17/24/17 0.17 -19.05%
16/24/16 0.21 +10.53%
15/24/15 0.19 -9.52%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 01:01 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL7YWB
ISINDE000JL7YWB2
Date issued 26/07/2023
Strike 320 $
Maturity 17/01/2025 (242 Days)
Parity 10 : 1
Emission price 1.53
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.53
Lowest since issue 0.17
Spread 0.5
Spread %74.63%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW